XML 42 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangible Assets
12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Goodwill and Intangible Assets
The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:
 
Weighted-Average Life (Years)
 
Original Cost
 
Accumulated Amortization
 
Net Book Value
Definite-lived intangible assets
 
 
 
 
 
 
 
Distribution right
20
 
$
59,076

 
$
(2,679
)
 
$
56,397

Capitalized software
2
 
4,415

 
(1,174
)
 
3,241

Intangible assets, net
 
 
63,491

 
(3,853
)
 
59,638

Indefinite-lived intangible asset
 
 
 
 
 
 
 
Goodwill
*
 
21,208

 

 
21,208

Total as of December 31, 2019
 
 
$
84,699

 
$
(3,853
)
 
$
80,846

 
Weighted-Average Life (Years)
 
Original Cost
 
Accumulated Amortization
 
Net Book Value
Indefinite-lived intangible assets
 
 
 
 
 
 
 
IPR&D**
*
 
$
56,076

 
$

 
$
56,076

Goodwill
*
 
21,208

 

 
21,208

Total as of December 31, 2018
 
 
$
77,284

 
$

 
$
77,284

________________________
* Intangible assets with indefinite lives have an indeterminable average life.
** IPR&D is presented as “intangible assets, net” in the accompanying balance sheets.
The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2019 that are subject to amortization:
Fiscal year
 
2020
$
5,423

2021
3,729

2022
2,955

2023
2,955

2024
2,955

Thereafter
41,621

 
$
59,638


In connection with the acquisition of the Company by SCH in 2013, the Company recorded goodwill of $21,208 and IPR&D of $56,076. The IPR&D recognized represents the license and associated distribution right to develop Jeuveau®, the initial term of which expires in September 2023 and is automatically extended for unlimited additional three-year terms provided that the Company meets certain performance requirements. Additionally, pursuant to the Daewoong Agreement, up to $13,500 in additional cash consideration was due to Daewoong based upon the Company’s successful completion of certain technical and sales milestones. Upon FDA approval of Jeuveau® on February 1, 2019, the Company paid Daewoong a $2,000 milestone payment which increased the cost basis of the IPR&D, and the IPR&D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of 20 years. In connection with EU approval of Jeuveau®, the Company paid a $1,000 milestone payment to Daewoong in the fourth quarter of fiscal year 2019, which also increased the cost basis of the distribution right.
For the years ended December 31, 2019 and 2018, the Company capitalized $4,415 and $0, respectively, related to costs of computer software developed for internal use. The software is amortized over a two-year period using the straight-line method. For the years ended December 31, 2019 and 2018, total intangible assets amortization expense of $3,853 and $0 was recorded within depreciation and amortization on the accompanying statements of operations and comprehensive loss, respectively.